+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families

Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families

Journal of Clinical Oncology 26(15_Suppl): 22108-22108

NlmCategory="UNASSIGNED">22108 Background: Breast cancer (BC) is a significant health care problem in Brazil and only a few studies have been conducted to verify the contribution of founder mutations in BRCA genes to the occurrence of these tumors, especially in high risk families. Two recent studies in the State of Rio de Janeiro described a higher than expected prevalence of the BRCA founder mutations usually seen in individuals of Ashkenazi Jewish origin in non-Jewish breast cancer-affected women. The largest of these studies, conducted by Gomes et al., described a prevalence of 2.3% of the BRCA1 mutation 5382insC these patients were unselected for family history of the disease. Patients affected with breast cancer or other tumors of the HBOC spectrum, whose familiy histories fulfilled the ASCO criteria for HBOC and/or who had a prior probability of carryng a BRCA mutation ≥30% (using the Myriad prevalence tables and/or the Penn II model) were recruited from high risk genetics clinics in the cities of Rio de Janeiro and São Paulo. All patients denied Ashkenazi Jewish ancestry. Mutation detection was performed by PCR-amplification of the regions of interest in BRCA1 and BRCA2 followed by DNA sequencing. All mutations were confirmed in an independent sample. A total of 145 unrelated patients were tested. None of them carried the 185delAG or 6174delT mutations in BRCA1 and BRCA2, respectively. Five (5) patients carried the BRCA1 mutation 5382insC in the germline, resulting in a prevalence of 3.44% for this mutation in the HBOC families studied. Testing for the three common BRCA founder mutations in non-Ashkenazi Brazilian women is probably not justified, especially not for the 185delAG and 6174delT mutations; the BRCA1 mutation 5382insC however, was relatively frequent. Additional haplotyping studies will be necessary to determine if these mutants share a common haplotype with those identified in individuals of Ashkenazi origin. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 058615558

Download citation: RISBibTeXText

PMID: 27950803

Related references

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2): 97-102, 2006

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Hereditary Cancer in Clinical Practice 16: 12, 2018

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics 63(5): 1341-1351, 1998

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile. Oncotarget 8(43): 74233-74243, 2017

Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation 15(5): 480-481, 2000

Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics 60(5): 1059-1067, 1997

Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. International Journal of Cancer 86(5): 737-740, June 1, 2000

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. Journal of Medical Genetics 39(8): 611-614, 2002

Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 07 percent combined BRCA1 founder mutation frequency is reported in a Jewish cohort. American Journal of Human Genetics 59(4 SUPPL ): A28, 1996

Prevalence of BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish (AJ) families with breast cancer (BC) and pancreatic cancer (PC). Journal of Clinical Oncology 23(16_Suppl): 9549-9549, 2016

BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncologica 47(4): 772-777, 2008

Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations. Genes, Chromosomes and Cancer 45(9): 791-797, 2006

The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada. Bulletin du Cancer 93(9): 841-846, 2006

Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. International Journal of Oncology 41(5): 1619-1627, 2013

A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. Casopis Lekaru Ceskych 139(20): 635-637, 2001